Honest Comparison · June 2026
REMEVi vs. Ivy Rx
We compared pricing, bilingual support, licensing, and care across both platforms — including where Ivy Rx advertises a lower headline price. Here's exactly what we found, no spin.
Side-by-side
REMEVi vs. Ivy Rx feature by feature
Based on publicly available data, pricing pages, and patient reviews — June 2026.
| Feature | REMEVi | Ivy Rx |
|---|---|---|
| Semaglutide — lowest advertised | ✅ $199/mo (52-wk) · $279/mo monthly — all-inclusive | ~$155/mo (microdose) · ~$175/mo standard |
| Tirzepatide — lowest advertised | ✅ $269/mo (52-wk) · $379/mo monthly | ~$297+/mo (lowest tied to 12-mo prepay) |
| Lowest price requires long prepay? | ✅ No — monthly option, cancel anytime | ⚠️ Lowest tirzepatide needs prepay |
| Separate membership fee | ✅ None — care, meds & shipping bundled | ✅ None |
| Spanish-language support | ✅ Fully bilingual (built-in) | ❌ No Spanish support found (Jun 2026) |
| Bilingual care coordinator | ✅ Assigned to every patient | ❌ Not offered |
| LegitScript certified | ✅ Certified | ✅ Certified |
| All-inclusive price | ✅ Yes — one all-inclusive price | ✅ Yes |
Pricing and features subject to change. Competitor prices are approximate — always verify current pricing on each provider's website.
The bilingual difference
Built bilingual — not retrofitted
We did not find Spanish-language support advertised on Ivy Rx as of June 2026. REMEVi was built bilingual from the ground up. Every intake form, provider note, care coordinator message, and patient touchpoint is available in fluent English and Spanish.
GLP-1 programs
How the GLP-1 programs compare
Both REMEVi and Ivy Rx offer compounded semaglutide and tirzepatide for weight loss, prescribed by licensed US providers and prepared by state-licensed compounding pharmacies. What differs is the experience around the medication: headline pricing, what's bundled into that price, language support, licensing breadth, and response time.
On price — candidly: Ivy Rx advertises a lower headline semaglutide price, around $155/month for a microdose option and roughly $175/month standard, compared with REMEVi's semaglutide at $199/month on the 52-week plan ($279/month month-to-month). If the single lowest semaglutide sticker price is your only priority, Ivy Rx advertises less. REMEVi's price reflects what's included: native bilingual care, a dedicated coordinator, nationwide licensing, and faster support — all in one all-inclusive number.
On tirzepatide: REMEVi is competitive at $269/month on the 52-week plan ($379/month month-to-month). Ivy Rx's lowest advertised tirzepatide is approximately $297+/month, and that lowest tier is tied to a 12-month prepay. REMEVi keeps a monthly option you can cancel anytime, so the lowest price doesn't require a long commitment.
On support: REMEVi assigns every patient a dedicated bilingual care coordinator with a 2-hour response target. For patients managing side effects, dosage questions, or medication concerns, response time matters significantly.
On licensing: REMEVi is licensed to provide care across all 50 states plus the District of Columbia — full nationwide coverage. Always confirm a provider serves your state before you start.
On language: We did not find Spanish-language support advertised on Ivy Rx as of June 2026. REMEVi's entire platform — intake forms, clinical summaries, medication instructions, care coordinator communications — is available natively in English and Spanish. For the 62 million Spanish-speaking Americans, this is not a minor feature. It is a fundamental difference in the quality of care they receive.
FAQ
Common questions
For many patients, yes — especially if you value bilingual care and broad licensing. REMEVi is built natively bilingual in English and Spanish, is licensed across all 50 states plus DC, assigns every patient a dedicated bilingual care coordinator, and targets a 2-hour support response. Pricing is all-inclusive — clinical review, medication, shipping, and support in one number — with a month-to-month option you can cancel anytime. Compare the experience and the all-in price for your situation.
We want to be candid: Ivy Rx advertises a lower headline semaglutide price (around $155/month microdose, ~$175/month standard) than REMEVi's semaglutide ($199/month on a 52-week plan, $279/month month-to-month). Where REMEVi competes is on what that price includes — native bilingual English and Spanish care, licensing in all 50 states plus DC, a dedicated care coordinator, and a 2-hour response target. On tirzepatide, REMEVi is competitive at $269/month on the 52-week plan, while Ivy Rx's lowest advertised tirzepatide (around $297+/month) is tied to a 12-month prepay. Always verify current pricing on each provider's site, as telehealth pricing changes frequently.
We did not find Spanish-language support advertised on Ivy Rx as of June 2026. REMEVi is built natively bilingual — every intake form, care coordinator, and patient message is available in English and Spanish from day one. If Spanish-language care matters to you or your family, that is a meaningful difference.
Yes — Ivy Rx markets oral "melt" formulations in addition to injectable options. REMEVi offers its own GLP-1 program, and the right option for you — oral or injectable, semaglutide or tirzepatide — is determined by a licensed provider based on your health history and goals, not chosen from a menu. Talk with a clinician about what fits your situation.
Both REMEVi and Ivy Rx are LegitScript certified, which is a meaningful third-party validation of a telehealth provider's legitimacy and compliance. Beyond that shared certification, REMEVi adds licensing across all 50 states plus DC and native bilingual care with a dedicated coordinator. We are not here to disparage Ivy Rx — both are legitimate options; the right fit depends on what you need.
Yes. Switching is straightforward — complete REMEVi's 5-minute intake form, a licensed provider reviews your case within 24 hours, and your medication ships within days. You do not need to formally cancel Ivy Rx before starting; simply time your transition to avoid overlapping charges. Compounded medications are non-FDA-approved preparations prepared by state-licensed compounding pharmacies and are not generic versions of, nor the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®.
Compare REMEVi with other GLP-1 providers
See how REMEVi stacks up on price, bilingual support, and transparency.
Ready to get started with REMEVi?
Clinical review in 24 hours. No insurance needed. Native bilingual care, nationwide licensing, and one all-inclusive price.
Start free consultation
